Cannabinoids and the Gastrointestinal Tract

被引:7
|
作者
Camilleri, Michael [1 ,2 ]
Zheng, Ting [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Clin Enter Neurosci Translat & Epidemiol Res, Rochester, MN 55905 USA
[2] Mayo Clin, 200 First St SW,Charlton Bldg,Room 8-110, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Cannabis; Gastroparesis; Inflammatory Bowel eases; Nausea; Vomiting; Pain Disorders; INFLAMMATORY-BOWEL-DISEASE; CHRONIC NEUROPATHIC PAIN; ENDOCANNABINOID SYSTEM; CROHNS-DISEASE; DOUBLE-BLIND; RECEPTORS; CANNABIDIOL; HYPEREMESIS; AGONIST; CONTRACTILITY;
D O I
10.1016/j.cgh.2023.07.031
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The synthesis and degradation of endocannabinoids, location of cannabinoid (CB) receptors, and cannabinoid mechanisms of action on immune/inflammatory, neuromuscular, and sensory functions in digestive organs are well documented. CB2 mechanisms are particularly relevant in immune and sensory functions. Increasing use of cannabinoids in the United States is impacted by social determinants of health including racial discrimination, which is associated with tobacco and cannabis co-use, and combined use disorders. Several conditions associated with emesis are related to cannabinoid use, including cannabinoid hyperemesis or withdrawal, cyclic vomiting syndrome, and nausea and vomiting of pregnancy. Cannabinoids generally inhibit gastrointestinal motor function; yet they relieve symptoms in patients with gastroparesis and diverse nausea syndromes. Cannabinoid effects on inflammatory mechanisms have shown promise in relatively small placebo-controlled studies in reducing disease activity and abdominal pain in patients with inflammatory bowel disease. Cannabinoids have been studied in disorders of motility, pain, and disorders of gut-brain interaction. The CB2-receptor agonist, cannabidiol, reduced the total Gastroparesis Cardinal Symptom Index and increases the ability to tolerate a meal in patients with gastroparesis appraised over 4 weeks of treatment. In contrast, predominant-pain end points in functional dyspepsia with normal gastric emptying were not improved significantly with cannabidiol. The CB2 agonist, olorinab, reduced abdominal pain in inflammatory bowel disease in an openlabel trial and in constipation-predominant irritable bowel syndrome in a placebo-controlled trial. Cannabinoid mechanisms alter inflammation in pancreatic and liver diseases. In conclusion, cannabinoids, particularly agents affecting CB2 mechanisms, have potential for inflammatory, gastroparesis, and pain disorders; however, the trials require replication and further understanding of riskdiseases.
引用
收藏
页码:3217 / 3229
页数:13
相关论文
共 50 条
  • [1] The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility
    Abalo, Raquel
    Vera, Gema
    Lopez-Perez, Ana Esther
    Martinez-Villaluenga, Maria
    Martin-Fontelles, Maria Isabel
    PHARMACOLOGY, 2012, 90 (1-2) : 1 - 10
  • [2] Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases
    Maselli, Daniel B.
    Camilleri, Michael
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (09) : 1748 - +
  • [3] Cannabinoids
    Howard, Paul
    Twycross, Robert
    Shuster, John
    Mihalyo, Mary
    Wilcock, Andrew
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2013, 46 (01) : 142 - 149
  • [4] Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans
    Camilleri, M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30 (09):
  • [5] Cannabinoids for gastrointestinal diseases: potential therapeutic applications
    Di Carlo, G
    Izzo, AA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (01) : 39 - 49
  • [6] Cannabinoids A Guide for Use in the World of Gastrointestinal Disease
    Unal, Ece
    Anderson, Brigitte
    Helber, Andrew
    Marks, John H.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2020, 54 (09) : 769 - 788
  • [7] Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation
    Gyires, Klara
    Zadori, Zoltan S.
    CURRENT NEUROPHARMACOLOGY, 2016, 14 (08) : 935 - 951
  • [8] Cannabis and the Gastrointestinal Tract
    Cohen, Lawrence B.
    Neuman, Manuela G.
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2020, 23 : 304 - 313
  • [9] CANNABINOIDS AS ANTIEMETICS: A SHORT REVIEW
    Liano, Hugo Calavia
    Zakowicz, Przemyslaw
    Mikolajczak, Przemyslaw
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (05): : 1063 - 1068
  • [10] Effects of Cannabinoids on Intestinal Motility, Barrier Permeability, and Therapeutic Potential in Gastrointestinal Diseases
    Crowley, Kijan
    Kiraga, Lukasz
    Miszczuk, Edyta
    Skiba, Sergiusz
    Banach, Joanna
    Latek, Urszula
    Mendel, Marta
    Chlopecka, Magdalena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)